Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

CompletedOBSERVATIONAL

Enrollment

716

Participants

Timeline

Start Date

January 17, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Melanoma

Interventions

DRUG

Encorafenib

450 mg QD

DRUG

Binimetinib

45 mg BID

DRUG

Vemurafenib

960 mg BID for 28 days/cycle

DRUG

Cobimetinib

60 mg QD for 21 days/cycle

DRUG

Dabrafenib

150 mg BID

DRUG

Trametinib

2 mg QD

Trial Locations (1)

Pfizer Investigational Site, New York